Penso L, Dray-Spira R, Weill A, et al. - It was shown that systemic treatments for psoriasis (including biologics) were not correlated with an elevated risk of in-hospital mortality due to COVID-19. During the pandemic, data support maintaining systemic treatment for psoriasis.

• Researchers distinguished 1,326,312 patients with psoriasis (mean age 59 years; males, 48%).

• Furthermore, 3871 patients were hospitalized for COVID-19 and 759 (20%) died during the first study period, while 3603 were hospitalized for COVID-19 and 686 (19%) died during the second period.

• The risk of hospitalization for COVID-19 was associated with exposure to topicals or nonbiologic [hazard ratio (95% confidence interval): 1·11 (1·04–1·20) and 1·27 (1·09–1·48), respectively] during the first period, and with all exposure types, during the second period in the propensity score-weighted Cox models.

• Due to COVID-19, none of the exposure types was correlated with in-hospital mortality.